Candidozyma auris (C. auris) is an emerging healthcare-associated yeast of major epidemiological concern because of its multidrug resistance and outbreak potential. We report the recovery of a single C. auris isolate from a used face mask collected in May 2025 during a blinded dental medicine quality-control programme assessing microbial contamination in the working environment. To contextualise this finding, we analysed routine diagnostic laboratory data from 2017 to 2025. The isolate underwent whole-genome sequencing for molecular characterisation, including analysis of the ERG11 gene, and antifungal susceptibility testing by EUCAST broth microdilution. In addition, 53,802 patient-related Candida spp. isolates collected between 2017 and 2025 were reviewed retrospectively; species identification had been performed by MALDI-TOF. The environmental isolate belonged to clade III and carried the V125A/F126L substitutions in ERG11, consistent with African clade isolates and associated with intrinsically high fluconazole minimum inhibitory concentrations. No C. auris was detected in routine patient specimens during the study period, whereas Candida albicans remained the predominant species in clinical samples. These findings provide no evidence of ongoing C. auris transmission at the Medical University of Innsbruck, but highlight the need for continued vigilance and robust infection-prevention measures to limit the risk posed by isolated introductions.
Bauer et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: